provera medroxyprogesterone acetate 10mg tablet
pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; calcium stearate; liquid paraffin; sucrose; purified talc; maize starch - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.
provera medroxyprogesterone acetate 5mg tablet
pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 5 mg - tablet, uncoated - excipient ingredients: indigo carmine; maize starch; sucrose; purified talc; liquid paraffin; calcium stearate; lactose monohydrate - 1. carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4. abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.
provera medroxyprogesterone acetate 2.5mg tablet
pfizer australia pty ltd - medroxyprogesterone acetate, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; purified talc; calcium stearate; liquid paraffin; maize starch; sunset yellow fcf; sucrose - 1.carcinoma: palliative treatment of recurrent and/or metastatic breast or renal cell cancer and of inoperable recurrent or metastatic endometrial carcinoma. 2. endometriosis: for use in the treatment of visually proven (laparoscopy) endometriosis where the required end-point of treatment is pregnancy, or for the control of symptoms when surgery is contraindicated or has been unsuccessful. 3. secondary amenorrhoea proven not due to pregnancy: in amenorrhoea associated with a poorly developed proliferative endometrium, conventional oestrogen therapy may be employed in conjunction with medroxyprogesterone acetate. 4.abnormal uterine bleeding: in the absence of organic pathology. 5. adjunct to oestrogen therapy: combination hormone replacement therapy should only be used in non-hysterectomised women.
mirena
bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.
mirena
bayer israel ltd - levonorgestrel - intrauterine device - levonorgestrel 52 mg - levonorgestrel and estrogen - contraception and idiopathic menorrhagia. protection from endometrial hyperplasia during estrogen replacement therapy.
dostinex
pfizer pfe pharmaceuticals israel ltd - cabergoline - tablets - cabergoline 0.5 mg - cabergoline - cabergoline - treatment of hyperprolactinemic disorders.dostinex is indicated for the treatment of dysfunctions associated with hyperprolactinemia, including amenorrhea, oligomenorrhea, anovulation and galactorrhea. dostinex is indicated in patients with prolactin-secreting pituitary adenomas (micro-and macroprolactinomas), idiopathic hyperprolactinemia, or empty sella syndrome with associated hyperprolactinemia. inhibition and supression of lactation .
zoladex goserelin 3.6mg (as acetate) implant syringe
astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - prostate cancer: palliative treatment of metastatic or locally advanced prostate cancer , where suitable for hormonal manipulation. adjuvant and neo-adjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation. breast cancer: treatment of advanced breast cancer (t3b, t4 or any t with n2, 3 or m+) in premenopausal women suitable for hormonal manipulation. adjuvant therapy in early breast cancer, in pre- and perimenopausal women suitable for hormonal manipulation. endometriosis: in the management of visually proven endometriosis to reduce symptoms including pain and the size and number of endometrial lesions. uterine fibroids: in the management of fibroids, zoladex shrinks the lesions and reduces the symptoms, including pain. zoladex also increases the haemoglobin concentration and haematocrit in women with anaemia attributable to menorrhagia. it is used as an adjunct to surgery to facilitate the operative technique and reduce
vitex excel
mcpherson's consumer products pty ltd - vitex agnus-castus, quantity: 100 mg (equivalent: vitex agnus-castus, qty 1000 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; microcrystalline cellulose; carnauba wax; purified talc; maltodextrin; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; hypromellose; macrogol 400 - traditionally used in western herbal medicine to maintain/support female reproductive system health ; traditionally used in western herbal medicine to decrease/reduce/relieve menstrual cycle irregularity/irregular periods ; traditionally used in western herbal medicine to maintain/support/regulate healthy menstrual cycle ; traditionally used in western herbal medicine to decrease/reduce/relieve menstruation pain/dysmenorrhoea ; traditionally used in western herbal medicine to decrease/reduce/relieve breast pain/tenderness associated with premenstrual tension ; traditionally used in western herbal medicine to decrease/reduce/relieve symptoms of premenstrual tension
apo-bromocriptine
apotex nz ltd - bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) - tablet - 2.5 mg - active: bromocriptine mesilate 2.9mg equivalent to bromocriptine 2.5 mg (2.9 - 3.0 mg) excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose - prolactin dependent menstrual cycle disorders (amenorrhoea, oligomenorrhoea, galactorrhoea), and/or female infertility associated with hyperprolactinaemia or luteal phase deficiency: · bromocriptine may normalise the menstrual cycle and/or induce ovulation without ovarian overstimulation. treatment with bromocriptine is not curative and it is not effective in treating ovarian failure.
gonal-f 75 iu (5.5 mcg)
merck serono ltd - follitropin alfa - powder for solution for injection - follitropin alfa 5.5 mcg/dose - follitropin alfa - follitropin alfa - 1) gonal-f followed by chorionic gonadotrophin (hcg) is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. these women are classified as w.h.o group ii patients and usually receive clomiphene citrate as primary therapy. they have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. polycystic ovarian disease (pcod) is part of the who ii classification and is present in the majority of these patients. 2) gonal-f is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertillization (ivf) gamete intra-fallopian transfer (gift) and zogote intra-fallopian transfer (zift). 3) gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism.